Pulse Biosciences (PLSE) Investor presentation summary

Mission and vision

• Aims to design, produce, and commercialize next-generation therapeutic solutions using nanosecond pulsed field ablation (nsPFA) to improve and extend patient lives.

• Focuses on building first-in-class and best-in-class technologies with high quality and reliability.

• Seeks to positively impact patients, physicians, healthcare providers, shareholders, and team members.

Leadership and expertise

• Leadership team includes experienced technologists, operators, and clinicians from major medical device and healthcare companies.

• Board and scientific advisors bring expertise in electrophysiology, cardiac surgery, and head and neck specialties.

Financial and strategic position

• Cash and cash equivalents of $101.6 million as of June 30, 2026, with no debt.

• $18.7 million cash used in operating activities in Q2 2026; $57.5 million raised through ATM program by July 2026.

• Approximately 75% insider ownership.

• Strategic focus on EP ablation catheter clinical development and accelerating pivotal trial enrollment.